Miguel Regueiro, MD

Cleveland Clinic Main Campus

Poster(s):

• B0406 - Mirikizumab Demonstrates Sustained Improvement in Fatigue in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET

• B0407 - Improvement in Fatigue With Mirikizumab Therapy Is Associated With Improvements in Patient-Reported Outcomes in Patients With Moderately-to-Severely Active Crohn’s Disease
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET

• B0408 - Improvement in Fatigue With Mirikizumab Therapy Is Associated With Clinical Remission and Pain Improvements but Not With Endoscopic Response in Patients With Moderately-to-Severely Active Crohn’s Disease
  Monday, October 24, 2022

  10:00 AM – 12:00 PM ET